A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Cancer Recurrence, Clinical Trials, High Risk Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (MCSPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05679388
Phase: Phase 1
Trial Summary: Researchers leading this study hope to learn about the safety of combining the study drug relugolix with another study drug called itraconazole or ritonavir in prostate cancer. Thi – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Chicago
Acronym:

Pin It on Pinterest